Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial
Authors:
- Joyce OjedaJOJoyce Ojeda
- José Luis ArredondoJAJosé Luis Arredondo
- Perla SalcedoPSPerla Salcedo
- Mercedes Paredes-ParedesMPMercedes Paredes-Paredes
- Martin DupuyMDMartin Dupuy
- Celine PetitCPCeline Petit
- Anne Laure ChabanonACAnne Laure Chabanon
- Enrique RivasEREnrique Rivas
- Sanjay GurunathanSGSanjay Gurunathan
- Iris De BruijnIBIris De Bruijn
- Stephanie PepinSPStephanie Pepin
Open Access
- 20 December 2019
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 16 (6) , 1380-1384
Abstract
Annual vaccination is the most effective way to prevent seasonal influenza. Influenza vaccines in multi-dose vial (MDV) formats can facilitate timely vaccination of large populations by reducing per-dose costs and cold storage requirements compared to single-dose pre-filled syringe (PFS) formats. MDV vaccines require thiomersal or another preservative to prevent microbial contamination. We conducted a randomized, open-label trial in 302 healthy subjects aged 6 months to 17 years to evaluate the immunogenicity and safety of a quadrivalent influenza vaccine (QIV) in a thiomersal-containing MDV format compared to the licensed thiomersal-free PFS format. Subjects were randomly assigned in a 1:1 ratio to receive the MDV (n=153) or PFS (n=149) format. Post-vaccination hemagglutination inhibition titers for all four vaccine strains were ≥4.9-fold higher than baseline titers with no difference in magnitude between the MDV and PFS groups. Seroconversion rates per strain were also comparable between the two groups. There were no differences in reactogenicity or safety between the two vaccine formats. These results showed that the MDV format of QIV was as safe and immunogenic as the PFS format in infants, children, and adolescents. These findings support the use of MDV QIV as a resource-saving alternative for seasonal influenza vaccination.Keywords
Funding Information
- Sanofi Pasteur (None)
This publication has 18 references indexed in Scilit:
- Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled studyHuman Vaccines & Immunotherapeutics, 2016
- Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trialVaccine, 2015
- Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adultsVaccine, 2013
- Vaccines against influenza WHO position paper – November 2012.2012
- Global Advisory Committee on Vaccine Safety, June 2012.2012
- The rationale for quadrivalent influenza vaccinesHuman Vaccines & Immunotherapeutics, 2012
- Vaccine presentation in the USA: economics of prefilled syringes versus multidose vials for influenza vaccinationExpert Review of Vaccines, 2010
- Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 YearsNew England Journal of Medicine, 2007
- Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries.2003
- Association Between Thimerosal-Containing Vaccine and AutismJAMA, 2003